Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ: LXRX )

0.7849 +0.0436 (+5.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Expectations For Lexicon Pharmaceuticals's Future
Via Benzinga
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Preview: Lexicon Pharmaceuticals's Earnings
Via Benzinga
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
Via Benzinga
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Via Benzinga
The Analyst Verdict: Lexicon Pharmaceuticals In The Eyes Of 8 Experts
Via Benzinga
Analyst Scoreboard: 6 Ratings For Lexicon Pharmaceuticals
Via Benzinga
5 Analysts Have This To Say About Lexicon Pharmaceuticals
Via Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
Via Benzinga
Topics Stocks
Exposures US Equities
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights
Via Benzinga
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Intel Reports Weak Results, Joins Amazon, Opendoor Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
Via Benzinga
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024
LXRX stock results show that Lexicon Pharmaceuticals met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.